Loading, Please Wait...
Dublin, March 13, 2018 (GLOBE NEWSWIRE) -- The "Global Central Nervous System Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Central Nervous System Partnering 2012 to 2018 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.
Global Central Nervous System Partnering 2012 to 2018 includes:
The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.
Deals and contracts are listed by:
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Central Nervous System dealmaking
2.2. Central Nervous System partnering over the years
2.3. Central Nervous System partnering by deal type
2.4. Central Nervous System partnering by industry sector
2.5. Central Nervous System partnering by stage of development
2.6. Central Nervous System partnering by technology type
2.7. Central Nervous System partnering by therapeutic indication
Chapter 3 -Financial deal terms for Central Nervous System partnering
3.2. Disclosed financials terms for Central Nervous System partnering
3.3. Central Nervous System partnering headline values
3.4. Central Nervous System deal upfront payments
3.5. Central Nervous System deal milestone payments
3.6. Central Nervous System royalty rates
Chapter 4 - Leading Central Nervous System deals and dealmakers
4.2. Most active in Central Nervous System partnering
4.3. List of most active dealmakers in Central Nervous System
4.4. Top Central Nervous System deals by value
Chapter 5 - Central Nervous System contract document directory
5.2. Central Nervous System partnering deals where contract document available
Chapter 6 - Central Nervous System dealmaking by therapeutic target
6.2. Deals by Central Nervous System therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/7wtgzd/global_central?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Central Nervous System Drugs